A5074043746- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Virus-based gene therapy research
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Cytomegalovirus and herpesvirus research
- Immunotherapy and Immune Responses
- CRISPR and Genetic Engineering
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- RNA Interference and Gene Delivery
- Viral Infectious Diseases and Gene Expression in Insects
- Chronic Myeloid Leukemia Treatments
- Polyomavirus and related diseases
- Immunodeficiency and Autoimmune Disorders
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 and COVID-19 Research
- Herpesvirus Infections and Treatments
- Viral-associated cancers and disorders
- Cancer Research and Treatments
- Nanowire Synthesis and Applications
- Mesenchymal stem cell research
- COVID-19 Clinical Research Studies
- Multiple Myeloma Research and Treatments
- Immune cells in cancer
Vita-Salute San Raffaele University
2016-2025
IRCCS Ospedale San Raffaele
2015-2025
San Raffaele University of Rome
2014-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2015-2025
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2015-2025
University of Rome Tor Vergata
2023-2025
International Society for Experimental Hematology
2012-2022
European Society for Blood and Marrow Transplantation
2022
Fondazione IRCCS Istituto Nazionale dei Tumori
2020
Universidade de São Paulo
2018
In allogeneic bone marrow transplantation (allo-BMT), donor lymphocytes play a central therapeutic role in both graft-versus-leukemia (GvL) and immune reconstitution. However, their use is limited by the risk of severe graft-versus-host disease (GvHD). Eight patients who relapsed or developed Epstein-Barr virus–induced lymphoma after T cell–depleted BMT were then treated with transduced herpes simplex virus thymidine kinase (HSV-TK) suicide gene. The survived for up to 12 months, resulting...
Transplantation of hematopoietic stem cells from partially matched family donors is a promising therapy for patients who have hematologic cancer and are at high risk relapse. The donor T-cell infusions associated with such transplantation can promote post-transplantation immune reconstitution control residual disease.
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers 47 countries to the 2014 survey. Trends include: continued growth transplant activity, more so Eastern European than west; a increase use haploidentical family donors (by 25%) and slower for unrelated donor HSCT. The cord blood as source has decreased again 2014. Main indications HSCT leukemias: 11 853 (33%; 96%...
Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade lymphoma mantle cell lymphoma. Products other diseases such as multiple myeloma follicular are likely to be by the European Medicines Agency near future.The Society Blood Marrow Transplantation (EBMT)-Joint Accreditation Committee of ISCT EBMT (JACIE) Haematology Association...
Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55′668 deaths in 114′491 patients HSCT (83.7% allogeneic) for leukemia were investigated landmark analysis causes of death at day 30 (very early), 100 (early), 1 year (intermediate) 5 years (late). Mortality from all decreased cohort (1980–2001) 2 (2002–2015) post-transplant phases autologous HSCT. After allogeneic HSCT,...
Oncogenic JAK mutation sensitizes myeloproliferative neoplasms to immune checkpoint inhibition.
A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43%) and 19 859 autologous (57%)) were reported by 658 centers 48 countries to the 2013 survey. Trends include: more growth than HSCT, increasing use sibling unrelated donors a pronounced increase haploidentical family when compared with cord blood for those without matched related or donor. Main indications leukemias, 11 190 (32%; 96% allogeneic); lymphoid neoplasias, 958 (57%; 11% solid tumors, 1543 (4%; 4% nonmalignant...
Abstract The major cause of death after allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for acute myeloid leukemia (AML) is disease relapse. We investigated the expression Inhibitory Receptors (IR; PD-1/CTLA-4/TIM-3/LAG-3/2B4/KLRG1/GITR) on T cells infiltrating bone marrow (BM) 32 AML patients relapsing (median 251 days) or maintaining complete remission (CR; median 1 year) HSCT. A higher proportion early-differentiated Memory (T SCM ) and Central BM-T express multiple IR in than...
Chimeric antigen receptor (CAR) T cell expansion and persistence represent key factors to achieve complete responses prevent relapses. These features are typical of early memory cells, which can be highly enriched through optimized manufacturing protocols. Here, we investigated the efficacy safety profiles CAR products generated from preselected naive/stem cells (TN/SCM), as compared with unselected (TBULK). Notwithstanding their reduced effector signature in vitro, limiting TN/SCM doses...